Payment overview · 2025
General Payments
$2,981.35
117 reported records · 25 companies
Healthcare provider profile · identity verified
Jennifer K Lynch, MD
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Neurology · SPRINGFIELD, MO · NPI 1700829165
Verified facts
What the public records show
CMS Open Payments records show Jennifer K Lynch, MD received $2,981.35 in general payments during 2025 across 117 reported records.
JAZZ PHARMACEUTICALS INC. accounted for 13.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 33 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Briviact, Epidiolex, Nayzilam, Nurtec Odt, Qulipta, Sunosi, Ubrelvy, Xcopri, Xywav.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Qulipta by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Ubrelvy by this doctor in 2024.
Axsome Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Sunosi as an associated drug or biological on 19758 records involving 6305 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Sunosi by this doctor in 2024.
JAZZ PHARMACEUTICALS INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported EPIDIOLEX as an associated drug or biological on 10990 records involving 3626 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Epidiolex by this doctor in 2024.
JAZZ PHARMACEUTICALS INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XYWAV as an associated drug or biological on 19511 records involving 5343 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Xywav by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Nurtec Odt by this doctor in 2024.
SK Life Science, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XCOPRI as an associated drug or biological on 1992 records involving 782 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Xcopri by this doctor in 2024.
UCB, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Briviact as an associated drug or biological on 13595 records involving 4444 distinct recipient NPIs. Public Medicare Part D data also shows 81 claims for Briviact by this doctor in 2024.
UCB, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Nayzilam as an associated drug or biological on 9542 records involving 3826 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Nayzilam by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| JAZZ PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $415.96 | 13.9% | 11 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $306.09 | 10.3% | 16 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $253.60 | 8.5% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $252.25 | 8.5% | 18 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $220.88 | 7.4% | 8 | 2025 |
| EMD Serono, Inc. | Unresolved — no canonical attribution shown | $184.70 | 6.2% | 9 | 2025 |
| SK Life Science, Inc. |
SK Life Science, Inc. exact · evidence 2025-04-03 |
$143.33 | 4.8% | 2 | 2025 |
| ARGENX US, INC. | Unresolved — no canonical attribution shown | $137.69 | 4.6% | 7 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $137.32 | 4.6% | 5 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $135.03 | 4.5% | 7 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $121.70 | 4.1% | 1 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $101.81 | 3.4% | 4 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $76.61 | 2.6% | 3 | 2025 |
| HARMONY BIOSCIENCES LLC | Unresolved — no canonical attribution shown | $75.05 | 2.5% | 3 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $73.15 | 2.5% | 3 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $69.94 | 2.4% | 4 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $61.12 | 2.0% | 3 | 2025 |
| LivaNova USA, Inc. | Unresolved — no canonical attribution shown | $46.40 | 1.6% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $38.82 | 1.3% | 2 | 2025 |
| Celgene Corporation | Unresolved — no canonical attribution shown | $31.86 | 1.1% | 2 | 2025 |
| MDD US Operations, LLC | Unresolved — no canonical attribution shown | $29.25 | 1.0% | 1 | 2025 |
| Merz Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $23.60 | 0.8% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $16.03 | 0.5% | 1 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $15.18 | 0.5% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $13.98 | 0.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,891.36 | 116 |
| Education | $89.99 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| XYWAV Normalized: xywav |
Drug | JAZZ PHARMACEUTICALS INC. | $319.63 | 7 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $253.60 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $252.25 | 18 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $252.25 | 18 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $180.95 | 6 | 2025 |
Source payment records
|
|||||
| BOTOX Normalized: botox |
Biological | ABBVIE INC. | $155.45 | 8 | 2025 |
Source payment records
|
|||||
| XCOPRI Normalized: xcopri |
Drug | SK Life Science, Inc. | $143.33 | 2 | 2025 |
Source payment records
|
|||||
| VYVGART HYTRULO Normalized: vyvgart hytrulo |
Drug | ARGENX US, INC. | $137.69 | 7 | 2025 |
Source payment records
|
|||||
| UPLIZNA Normalized: uplizna |
Biological | Amgen Inc. | $121.70 | 1 | 2025 |
Source payment records
|
|||||
| VUMERITY Normalized: vumerity |
Drug | Biogen, Inc. | $101.81 | 4 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $98.53 | 5 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $98.51 | 5 | 2025 |
Source payment records
|
|||||
| EPIDIOLEX Normalized: epidiolex |
Drug | JAZZ PHARMACEUTICALS INC. | $96.33 | 4 | 2025 |
Source payment records
|
|||||
| AMYVID Normalized: amyvid |
Drug | Lilly USA, LLC | $90.48 | 1 | 2025 |
Source payment records
|
|||||
| Rystiggo Normalized: rystiggo |
Drug | UCB, Inc. | $78.44 | 4 | 2025 |
Source payment records
|
|||||
| KESIMPTA Normalized: kesimpta |
Drug | Novartis Pharmaceuticals Corporation | $76.61 | 3 | 2025 |
Source payment records
|
|||||
| WAKIX Normalized: wakix |
Drug | HARMONY BIOSCIENCES LLC | $75.05 | 3 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $73.15 | 3 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $69.94 | 4 | 2025 |
Source payment records
|
|||||
| Sunosi Normalized: sunosi |
Drug | Axsome Therapeutics, Inc. | $61.12 | 3 | 2025 |
Source payment records
|
|||||
| VNS THERAPY SENTIVA MODEL 1000 GENERATOR Normalized: vns therapy sentiva model 1000 generator |
Device | LivaNova USA, Inc. | $46.40 | 2 | 2025 |
Source payment records
|
|||||
| EMGALITY Normalized: emgality |
Drug | Lilly USA, LLC | $39.93 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $38.82 | 2 | 2025 |
Source payment records
|
|||||
| Briviact Normalized: briviact |
Drug | UCB, Inc. | $36.98 | 2 | 2025 |
Source payment records
|
|||||
| ZEPOSIA Normalized: zeposia |
Drug | Celgene Corporation | $31.86 | 2 | 2025 |
Source payment records
|
|||||
| Gocovri Normalized: gocovri |
Drug | MDD US Operations, LLC | $29.25 | 1 | 2025 |
Source payment records
|
|||||
| TYSABRI Normalized: tysabri |
Biological | Biogen, Inc. | $28.69 | 1 | 2025 |
Source payment records
|
|||||
| Xeomin Normalized: xeomin |
Biological | Merz Pharmaceuticals, LLC | $23.60 | 1 | 2025 |
Source payment records
|
|||||
| Nayzilam Normalized: nayzilam |
Drug | UCB, Inc. | $19.61 | 1 | 2025 |
Source payment records
|
|||||
| INFINITY Normalized: infinity |
Device | Abbott Laboratories | $16.03 | 1 | 2025 |
Source payment records
|
|||||
| CREXONT Normalized: crexont |
Drug | Amneal Pharmaceuticals LLC | $15.18 | 1 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $13.98 | 1 | 2025 |
Source payment records
|
|||||
| VYALEV Normalized: vyalev |
Drug | ABBVIE INC. | $7.08 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Briviact briviact |
2025 | Briviact | 2024 | 81 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| EPIDIOLEX epidiolex |
2025 | Epidiolex | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Nayzilam nayzilam |
2025 | Nayzilam | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 71 | exact normalized | Medicare Part D |
| QULIPTA qulipta |
2025 | Qulipta | 2024 | 36 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Sunosi sunosi |
2025 | Sunosi | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 37 | exact normalized | Medicare Part D |
| XCOPRI xcopri |
2025 | Xcopri | 2024 | 43 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| XYWAV xywav |
2025 | Xywav | 2024 | 28 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
37 | 11 |
| Axsome Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | Sunosi open payments reported associated product |
CMS Open Payments — General Payments 19758 supporting records · 6305 recipient NPIs · example record 1235293059 |
Sunosi · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| JAZZ PHARMACEUTICALS INC. Exact reporting entity; no affiliate inference |
2025 | EPIDIOLEX open payments reported associated product |
CMS Open Payments — General Payments 10990 supporting records · 3626 recipient NPIs · example record 1234297758 |
Epidiolex · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| JAZZ PHARMACEUTICALS INC. Exact reporting entity; no affiliate inference |
2025 | XYWAV open payments reported associated product |
CMS Open Payments — General Payments 19511 supporting records · 5343 recipient NPIs · example record 1234297700 |
Xywav · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
71 | 19 |
| SK Life Science, Inc. Exact reporting entity; no affiliate inference |
2025 | XCOPRI open payments reported associated product |
CMS Open Payments — General Payments 1992 supporting records · 782 recipient NPIs · example record 1252276115 |
Xcopri · 2024 Exact normalized brand match · 1 Part D row |
43 | suppressed by CMS |
| UCB, Inc. Exact reporting entity; no affiliate inference |
2025 | Briviact open payments reported associated product |
CMS Open Payments — General Payments 13595 supporting records · 4444 recipient NPIs · example record 1224348489 |
Briviact · 2024 Exact normalized brand match · 1 Part D row |
81 | suppressed by CMS |
| UCB, Inc. Exact reporting entity; no affiliate inference |
2025 | Nayzilam open payments reported associated product |
CMS Open Payments — General Payments 9542 supporting records · 3826 recipient NPIs · example record 1224348539 |
Nayzilam · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 346 | 80 |
| Lamotrigine | Lamotrigine | 248 | 51 |
| Levetiracetam | Levetiracetam | 189 | 52 |
| Memantine Hcl | Memantine Hcl | 188 | 46 |
| Pregabalin | Pregabalin | 186 | 38 |
| Donepezil Hcl | Donepezil Hcl | 178 | 61 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 146 | 50 |
| Topiramate | Topiramate | 137 | 29 |
| Baclofen | Baclofen | 135 | 37 |
| Primidone | Primidone | 110 | 27 |
| Clonazepam | Clonazepam | 106 | 30 |
| Trazodone Hcl | Trazodone Hcl | 104 | 27 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 91 | 12 |
| Tizanidine Hcl | Tizanidine Hcl | 83 | 27 |
| Briviact | Brivaracetam | 81 | suppressed |
| Atorvastatin Calcium | Atorvastatin Calcium | 74 | 23 |
| Clobazam | Clobazam | 72 | suppressed |
| Lacosamide | Lacosamide | 71 | 14 |
| Nurtec Odt | Rimegepant Sulfate | 71 | 19 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 65 | 20 |
| Amitriptyline Hcl | Amitriptyline Hcl | 62 | 16 |
| Modafinil | Modafinil | 59 | 19 |
| Rasagiline Mesylate | Rasagiline Mesylate | 59 | 17 |
| Aimovig Autoinjector | Erenumab-Aooe | 54 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 53 | 17 |
| Oxcarbazepine | Oxcarbazepine | 49 | 17 |
| Divalproex Sodium Er | Divalproex Sodium | 47 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 47 | 13 |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 46 | 18 |
| Emgality Pen | Galcanezumab-Gnlm | 45 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 45 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 44 | suppressed |
| Xcopri | Cenobamate | 43 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 40 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 39 | 12 |
| Zonisamide | Zonisamide | 39 | suppressed |
| Ropinirole Er | Ropinirole Hcl | 38 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 37 | 14 |
| Duloxetine Hcl | Duloxetine Hcl | 37 | 15 |
| Ubrelvy | Ubrogepant | 37 | 11 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 36 | suppressed |
| Qulipta | Atogepant | 36 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 35 | 11 |
| Memantine Hcl Er | Memantine Hcl | 35 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 34 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 34 | suppressed |
| Carbamazepine Er | Carbamazepine | 30 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 30 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 29 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 29 | suppressed |
| Alprazolam | Alprazolam | 28 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 28 | suppressed |
| Xywav | Sodium,calcium,mag,pot Oxybate | 28 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 26 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 24 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 24 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 22 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 22 | suppressed |
| Armodafinil | Armodafinil | 21 | suppressed |
| Lamotrigine Er | Lamotrigine | 21 | suppressed |
| Amantadine | Amantadine Hcl | 20 | suppressed |
| Diazepam | Diazepam | 20 | 14 |
| Divalproex Sodium | Divalproex Sodium | 20 | suppressed |
| Bupropion Xl | Bupropion Hcl | 19 | suppressed |
| Lorazepam | Lorazepam | 19 | suppressed |
| Teriflunomide | Teriflunomide | 19 | suppressed |
| Fentanyl | Fentanyl | 18 | suppressed |
| Mirtazapine | Mirtazapine | 18 | suppressed |
| Nuplazid | Pimavanserin Tartrate | 18 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 17 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 17 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 16 | suppressed |
| Eszopiclone | Eszopiclone | 16 | suppressed |
| Methadone Hcl | Methadone Hcl | 16 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 16 | suppressed |
| Nayzilam | Midazolam | 14 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 14 | suppressed |
| Epidiolex | Cannabidiol (Cbd) | 13 | suppressed |
| Methylprednisolone | Methylprednisolone | 13 | suppressed |
| Promethegan | Promethazine Hcl | 13 | suppressed |
| Rebif | Interferon Beta-1a/Albumin | 13 | suppressed |
| Vigabatrin | Vigabatrin | 13 | suppressed |
| Dalfampridine Er | Dalfampridine | 12 | suppressed |
| Kesimpta Pen | Ofatumumab | 12 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 12 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 11 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 11 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 11 | suppressed |
| Sunosi | Solriamfetol Hcl | 11 | suppressed |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,981.35 · 117 records | JAZZ PHARMACEUTICALS INC. | AMYVID, BOTOX, Briviact, CREXONT, EMGALITY, EPIDIOLEX, Gocovri, INFINITY, INSPIRE, KESIMPTA, KISUNLA, Leqembi, NURTEC ODT, Nayzilam, PURIFIED CORTROPHIN GEL, QULIPTA, REXULTI, Rystiggo, Sunosi, TYSABRI, UBRELVY, UPLIZNA, VNS THERAPY SENTIVA MODEL 1000 GENERATOR, VUMERITY, VYALEV, VYEPTI, VYVGART HYTRULO, WAKIX, XCOPRI, XYWAV, Xeomin, ZAVZPRET, ZEPOSIA | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Briviact play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error